Autophagy and radiosensitization in cancer by Sharma, Khushboo et al.
EXCLI Journal 2014;13:178-191 – ISSN 1611-2156 
Received: February 07, 2014, accepted: February 19, 2014, published: February 25, 2014 
 
 
178 
Review article: 
AUTOPHAGY AND RADIOSENSITIZATION IN CANCER 
 
Khushboo Sharma1, Rachel Goehe5, Jason M. Beckta2, Kristoffer Valerie2,4,  
David A. Gewirtz1,3,4* 
 
Virginia Commonwealth University 
1 - Departments of Pharmacology and Toxicology 
2 - Department of Radiation Oncology 
3 - Department of Medicine 
4 - Massey Cancer Center 
5 Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, 
MD, 20892 
 
* Corresponding author: David A. Gewirtz, Virginia Commonwealth University,  
Massey Cancer Center, 401 College St., Richmond, VA 23298, Ph: 804-740-7378,  
Fax: 804-827-1134; e-mail: gewirtz@vcu.edu 
 
ABSTRACT 
Autophagy is a natural self-degradative process by which cells eliminate misfolded proteins 
and damaged organelles. Autophagy has been shown to have multiple functions in tumor cells 
that may be dependent on the tumor type and the treatment conditions. Autophagy can have a 
cytoprotective role and be thought of as a survival mechanism or be cytotoxic in nature and 
mediate cell death. Radiation, one of the primary treatments for many different types of can-
cer, almost uniformly promotes autophagy in tumor cells. While autophagy produced in re-
sponse to radiation is often considered to be cytoprotective, radiation-induced autophagy has 
also been shown to mediate susceptibility to radiation. This review addresses the complexity 
of autophagy in response to radiation treatment in three different cancer models, specifically 
lung cancer, breast cancer and glioblastoma. A deeper understanding of the different roles 
played by autophagy in response to radiation should facilitate the development of approaches 
for enhancing the therapeutic utility of radiation by providing strategies for combination 
treatment with unique radiosensitizers as well as preventing the initiation of strategies which 
are likely to attenuate the effectiveness of radiation therapy.  
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OVERVIEW 
Autophagy is an evolutionarily con-
served process, which morphologically in-
volves the formation of double-membrane 
bound autophagic vacuoles or autophago-
somes (Levine and Klionsky, 2004; Mi-
zushima and Levine, 2010), that degrade 
and recycle proteins and cellular organelles 
by fusion with lysosomes (Levine and 
Klionsky, 2004; Mizushima and Levine, 
2010). Autophagy can play a critical role in 
cancer cell survival by allowing cells to 
survive under conditions of metabolic and 
genotoxic stress (Wilson et al., 2011; 
Michallet et al., 2011; Qiang et al., 2013; 
Fung et al., 2008). On the other hand, ex-
cessive autophagy or self-eating may para-
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doxically lead to a type of programmed cell 
death (PCD), or type II PCD, a distinct cel-
lular suicide pathway (Ouyang et al., 2012). 
In the case where autophagy induction 
serves a prosurvival function in response to 
genotoxic stress, inhibiting autophagy may 
chemosensitize and radiosensitize tumor 
cells, thus increasing the efficacy of treat-
ment (Janku et al., 2011; Palumbo and 
Comincini, 2013). Conversely, inducing 
autophagic cell death within transformed 
cells resistant to apoptosis may be a viable 
therapeutic strategy for these types of can-
cers.  
Ionizing radiation, which is effective in 
the treatment of multiple types of malig-
nancies, has been found to promote auto-
phagy in virtually every experimental tumor 
model system. The autophagy induced by 
radiation is generally thought to provide a 
cytoprotective function, which can be sup-
pressed to enhance the response to radiation 
(Paglin et al., 2001). However, there are 
also examples where the autophagy induced 
by either radiation alone or radiation in 
combination with another treatment modali-
ty results in cell death. This review will 
provide examples of the functional roles of 
autophagy induction by radiation in three 
experimental tumor cell models, specifical-
ly breast cancer, lung cancer, and gliobla-
stoma.  
 
LUNG CANCER 
Incidence and current treatments 
Lung cancer is one of the leading causes 
of cancer-related death in the United States. 
Lung cancer has a relatively poor prognosis 
with a very low median survival rate. Lung 
cancer can be either primary, originating in 
the lung itself, or secondary, originating 
elsewhere in the body and metastasizing to 
the lungs (lungcancer.org). Primary lung 
cancer can be either non-small cell lung 
cancer (NSCLC) or small cell lung cancer 
(SCLC) (lungcancer.org). NSCLC is more 
common and less aggressive, accounting 
for 80 % of lung cancers, but can be diffi-
cult to diagnose since it is asymptomatic in 
its early stages. SCLC accounts for 10-
20 % of disease incidence and is frequently 
associated with smoking (lungcancer.org; 
Pesch et al., 2012). However, this section of 
the review will be limited to a discussion of 
studies relating to non-small cell lung can-
cer. 
The standard treatment regime for 
NSCLC involves surgery but the majority 
of NSCLC patients are not eligible for sur-
gical resection; as such, radiation is one the 
most commonly used and efficacious strat-
egies for treatment of lung cancer (Peng et 
al., 2008; Shin et al., 2012; Sharieff et al., 
2013). Patients are generally treated with 
cumulative doses of ~ 60 Gy divided into 
1.8-2 Gy fractions, often in combination 
with the chemotherapeutic agents, cisplatin 
or paclitaxel. Unfortunately, current thera-
pies such as radiation and chemotherapy are 
usually only palliative (Saintigny and Burg-
er, 2012; Siegel et al., 2013); consequently 
there is a compelling need for the develop-
ment of alternative therapies, which might 
be more effective and selective. 
 
Manipulating autophagy as therapeutic 
strategy 
Cytoprotective autophagy and radiation 
resistance 
Recent studies by Kroemer’s group (Ko 
et al., 2013) have supported the cytoprotec-
tive function of radiation-induced autopha-
gy by demonstrating that inhibition of au-
tophagy induced by radiation increased the 
effectiveness of the radiation treatment. 
Knockdown of the autophagy related genes 
ATG5 and Beclin-1 resulted in radiosensiti-
zation, indicative of the fact that autophagy 
can prevent radiation induced cell death in 
H460 and A549 NSCLC cell lines. Studies 
in immunodeficient tumor bearing mice fur-
ther showed that tumors with defective au-
tophagy were more sensitive to radiation.  
Studies by Apel et al. (2008) demon-
strated an increase in autophagic vesicle 
formation in response to radiation in A549 
non-small cell lung cancer cells. Further-
more, autophagy was shown to be cytopro-
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tective in nature since the clonogenic sur-
vival fraction was increased when autopha-
gy related genes such as Atg3 and Atg12 
were inhibited. Interestingly, this effect was 
more pronounced in cells with mutant p53. 
As defective p53 could be related to pre-
vention of apoptosis, these studies suggest 
that survival in response to blocked auto-
phagy is likely to be more pronounced in 
situations where apoptosis is compromised. 
In this context, although p53 is well estab-
lished to have a central role in the promo-
tion of apoptosis, its involvement in au-
tophagy is less well defined (Rikiishi, 2012; 
Su et al., 2013). 
Studies by Cheng et al. (2013) in H1299 
non-small cell lung cancer cells with in-
duced p53 found that inhibition of autopha-
gy by 3-methyl adenine led to a significant 
reduction in cell viability after radiation, 
supporting its cytoprotective function. Fur-
thermore, inhibition of apoptosis by using 
Z-VAD increased tumor cell survival rate. 
Taken together, these studies support the 
pro-survival/protective role of autophagy 
induced by radiation in non-small cell lung 
cancer.  
Cytotoxic or cytostatic autophagy 
Given the relative radioresistance of 
NSCLC, a number of studies has been de-
signed to identify compounds which might 
sensitize resistant NSCLC cancer cells to 
radiation treatment. In all the studies indi-
cated below, radiosensitization was associ-
ated with an increase in autophagy. 
Kim et al. (2011) reported that the zinc 
ionophore, PCI-5002, could increase the 
radiosensitive fraction of PCI-500 NSCLC 
cells, an effect that was accompanied by 
increased autophagy and decreased caspa-
se-3 cleavage. PCI-5002 treatment also re-
duced the growth rate of xenografted tumor 
cells, indicating that this compound has the 
capacity to sensitize lung tumor cells to ra-
diation both in vitro and in vivo. Although 
the data support the premise that radiation 
sensitization was occurring through the 
promotion of autophagy, these studies did 
not directly assess whether inhibition of au-
tophagy could reverse the observed radio-
sensitization.  
Berberine, a major component of herbal 
medicine used to treat inflammation in Eu-
rope and Asia, has been shown to enhance 
radiosensitization of NSCLC cells both in 
vitro and invivo (Peng et al., 2008). Au-
tophagy induction was detected by acridine 
orange staining of autophagic vesicles, 
electron microscopy, and immunoblotting 
of LC3 while there was only a minor in-
crease in the extent of apoptosis. Of critical 
importance, the autophagy inhibitor, 3-
methyl adenine, was shown to reverse radi-
osensitization by berberine while radiosen-
sitization was not reversed by the broad 
spectrum apoptosis inhibitor, Z-VAD. Ber-
berine used in combination with radiation 
produced a substantial reduction in tumor 
volume compared to the tumor growth de-
lay by either radiation or berberine alone.  
Shin et al. (2012) utilized non-invasive 
aerosol gene delivery in an effort to im-
prove the effectiveness of radiation therapy 
in NSCLC. Overexpression of Beclin-1 via 
inhalation in combination with radiation led 
to a significant decrease in tumor progres-
sion via prolonged activation of autophagic 
cell death in a k-rasLA1 lung cancer mouse 
model. Increased autophagy was detected 
by TEM analysis and immunoblotting to 
assess levels of autophagy related genes. 
The combination treatment also resulted in 
a decrease in phospho-Akt, which further 
led to mTORC1 and mTORC2 down-
regulation. This observation is significant in 
that phosphorylation of Akt and mTOR has 
been known to correlate with tumor pro-
gression and tumorigenesis (Choe et al., 
2003). 
While apoptosis has long been thought 
to be the primary form of cell death in re-
sponse to radiation, it actually accounts for 
a minor portion of cell death in irradiated 
solid tumors (Verheij and Bartelink, 2000). 
In this context, Kim et al. (2006) showed 
that knockdown of the pro-apoptotic pro-
teins, Bak and Bax, increased lung tumor 
radiosensitivity in vitro, decreased mTOR-
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Akt signaling and increased expression of 
pro-autophagic genes such as the Atg-5-
Atg12 complex. These investigators further 
demonstrated that autophagy was the cell 
death mechanism that contributed to this 
radiosensitization by reversing the sensiti-
zation effects using both the pharmacologi-
cal inhibitor, 3-MA and by genetically si-
lencing the autophagy related genes, Atg5 
and Beclin-1. To further explore the poten-
tial of apoptosis inhibition to sensitize lung 
cancer for therapy, M867, a novel chemical 
caspase-3 inhibitor, was utilized in combi-
nation with radiation in vivo in a mouse 
hind limb xenograft tumor model, where it 
was shown that M867 in combination with 
radiation produced a prolonged tumor 
growth delay (Kim et al., 2008a). The use 
of caspase double knockout cells (caspase 
3/7 deficient) provided additional support 
for the conclusion that autophagy was the 
mechanism responsible for increased radio-
sensitivity. Irradiated DKO cells were 
shown to have elevated levels of autopha-
gy; while knockdown of autophagic genes 
such as ATG5 and Beclin-1 resulted in de-
creased sensitization while overexpression 
of these autophagy associated genes in-
creased radiosensitivity.  
In a study that addressed the potential 
utility of inhibiting both apoptosis and 
mTOR signaling to improve the efficacy of 
radiation therapy, Kim et al. (2008b) also 
showed that the H460 NSCLC cell line is 
more sensitive to radiation in the presence 
of a caspase inhibitor, Z-DEVD. Sensitivity 
was further increased when used in combi-
nation with RAD001, which caused an in-
crease in autophagy via the inhibition of 
mTOR. In vivo studies using H460 NSCLC 
cells as xenografts confirmed the outcome 
of the in vitro studies in that the combina-
tion of either Z-DEVD and radiation or 
RAD001 and radiation induced a significant 
delay in tumor growth compared to radia-
tion alone. These studies suggest that sensi-
tization can occur even if levels of apopto-
sis are significantly reduced. Autophagy 
induction (based on GFP-LC3 and LC3II 
protein levels) was significantly increased 
by the combination treatment of radiation, 
Z-DEVD and RAD001 both in vivo and in 
vitro. Of particular importance for support-
ing the role of autophagy induction in ra-
diosensitization, knock down of the autoph-
agy related genes ATG5 and Beclin-1 re-
versed radiosensitization. Studies by Moret-
ti et al. (2009) using H460 cells support 
these observations in that the broad-
spectrum caspase inhibitor Z-VAD radio-
sensitized H460 cells both in cell culture 
and in tumor-bearing animals.  
Clinical NSCLC specimens have been 
reported to have mutations in multiple on-
cogenes and tumor suppressors including 
EGFR, K-RAS and p53 (Scagliotti et al., 
2004; Choi et al., 2010). The epidermal 
growth factor receptor (EGFR) appears to 
play a central role in cell proliferation and 
growth as activation of EGFR leads to col-
lateral activation of several pro-survival 
signaling pathways (Scagliotti et al., 2004); 
therefore, inhibition of EGFR signaling 
pathways represents a promising cancer 
treatment strategy. Pre-clinical and clinical 
studies have provided evidence supporting 
the potential value of targeting EGFR sig-
naling to enhance the anti-tumor effects of 
radiation (Steiner et al., 2007). However, 
therapeutic resistance from a number of 
factors such as downstream or alternative 
signaling pathways remains an issue. Choi 
et al. (2010) have shown that simultaneous 
inhibition of both EGFR and K-RAS using 
RNA interference increased radio-sensiti-
vity in A549 and H460 NSCLC cell lines. 
This group had also previously reported 
that targeting Akt using siRNA increased 
radiosensitivity in EGFR or Ras activated 
cell lines (Kim et al., 2005). These investi-
gators further showed that inhibiting Akt 
interferes with DNA double strand break 
repair as measured by γ-H2AX foci induc-
tion and decline. Both autophagy and apop-
tosis were demonstrated to be the modes of 
cell death in this study, as inhibition of ei-
ther response rescued the cells from radio-
sensitization. This study makes it clear that 
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targeting more than one component of a 
tumor specific signaling pathway would 
likely be necessary to overcome radiation 
resistance (Kim et al., 2005)  
Recently, studies conducted in our la-
boratory have shown that combination 
treatment of radiation with vitamin D and 
its analog, EB 1089, led to an increase in 
radiosensitivity in NSCLC. We demonstrat-
ed that this sensitization appeared to be a 
consequence of the switch from cytoprotec-
tive autophagy induced by radiation alone 
to a novel ‘cytostatic’ form of autophagy by 
the combination of 1,25-D3 or EB 1089 
with radiation. Furthermore, we showed 
that both pharmacological inhibition, em-
ploying inhibitors such as chloroquine and 
bafilomycin, and genetic suppression by 
silencing autophagy related genes such as 
Atg5 and Beclin-1 sensitized NSCLC cells 
to radiation alone, but inhibition of the cy-
tostatic form of autophagy induced by the 
combination treatment reversed sensitiza-
tion (manuscript in preparation).  
 
Conclusions 
In summary, while it is clear that radia-
tion-induced autophagy can be cytoprotec-
tive in non-small cell lung cancer, sensitiza-
tion to radiation using various novel com-
pounds and strategies is often associated 
with promotion of autophagy. Given the 
double (or triple) edged nature of autopha-
gy, an improved understanding of molecu-
lar interactions that underline the mecha-
nism(s) by which autophagy functions 
could ultimately lead to the identification of 
new targets for both diagnostic and thera-
peutic approaches in non-small cell lung 
cancer.  
 
Breast cancer 
Current standard treatment 
Breast cancer is the second leading 
cause of cancer-related deaths among wom-
en in the United States, with over 39,000 
deaths estimated in 2013 (Siegel et al., 
2013). Along with surgery and chemother-
apy, radiation is a widely used component 
of cancer therapy and is a fundamental tool 
in the treatment of breast cancer. Although 
radiation is an effective modality in the 
treatment of breast cancer, there is always 
the likelihood of disease reoccurrence from 
the dysregulation of cell signaling pathways 
that promote tumor cell survival (Dent et 
al., 2003). For instance, chemotherapeutic 
agents that kill tumor cells primarily 
through the induction of apoptosis may be-
come less effective as the cell develops 
strategies to evade apoptosis (Fesick, 2005). 
Therefore, the possibility of activating al-
ternative cell death pathways holds prom-
ise. In recent years, studies have reported 
the activation of autophagy in tumor cells 
following anticancer therapies such as radi-
ation and chemotherapy (Paglin et al., 
2001; Wilson et al., 2011; Debnath, 2011) 
as well as nonconventional therapies (Gor-
ka et al., 2005).  
 
Manipulating autophagy as therapeutic 
strategy 
Cytoprotective autophagy and radiation 
resistance 
Recent studies have demonstrated that 
breast tumor resistance to anticancer thera-
pies, including chemotherapy and radiation, 
can be enhanced through the upregulation 
of autophagy (Wilson et al., 2011; Ouyang 
et al., 2012; Bristol et al., 2012). Increasing 
evidence suggests that autophagy inhibition 
augments cytotoxicity in combination with 
varying anticancer therapies including radi-
ation. A study by Chaachouay et al., (2011) 
on the role of autophagy in resistance of 
breast tumor cells to ionizing radiation 
found that radiation treatment of MDA-
MB-231 cells markedly increased the level 
of LC3-II and thus the process of autophagy 
as also demonstrated by acridine orange 
staining of autophagosomes and Western 
immunoblotting (Chaachouay et al., (2011). 
Moreover, pretreatment of radioresistant 
MDA-MB-231 cells with the early stage 
autophagy inhibitor, 3-methyl adenine or 
the late stage autophagy inhibitor, chloro-
quine, significantly reduced clonogenic 
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survival of irradiated cells (Chaachouay et 
al., 2011). Similarly, studies in our labora-
tory found that the autophagy induced by 
radiation alone was cytoprotective in that 
pre-treatment with chloroquine or genetic 
inhibition of Atg5 or Atg7 increased sensi-
tivity to radiation of both MCF-7 and ZR-
75-1 breast tumor cells (Wilson et al., 2011; 
Bristol et al., 2012).  
It is well known that autophagy is a 
multi-step process that appears to be regu-
lated by various signaling pathways (Cao et 
al., 2006; Botti et al., 2006). Specifically, 
the ER stress and mTOR signaling path-
ways have been shown to be activated in 
response to radiation in various cellular sys-
tems (Qin et al., 2010; Hoyer-Hansen and 
Jaattela, 2007). With regard to radiation in-
duced autophagy in breast cancer, studies 
by Nagelkerke et al. (2013) suggested that 
knockdown of the PERK/ATF4/LAMP3-
arm of the unfolded protein response (UPR) 
system as well as chemical inhibition of 
PERK radiosensitized MDA-MD-231 cells. 
An analysis of DNA damage repair proteins 
found that knockdown of LAMP3 attenuat-
ed the DNA damage response after radia-
tion. Confocal microscopy found that 
LAMP3 knockdown resulted in a marked 
decrease in γ-H2AX foci positive cells post 
radiation, indicating that the DNA damage 
repair signaling response is decreased. Alt-
hough the exact mechanism involving 
LAMP3 mediated radioresistance is not 
completely clear, LAMP3 is involved in 
autophagy while ATF4 is essential for hy-
poxia-induced autophagy (Rouschop et al., 
2010; Rzymski et al., 2010). Also, autopha-
gy has been shown to be necessary for 
DNA repair as induced DNA damage has 
been found to trigger autophagy and regu-
late the removal of DNA repair factors from 
the cells (Rodriguez-Rocha et al., 2011; 
Robert et al., 2011). These studies support 
the premise that interference with autopha-
gy signaling can potentially overcome radi-
oresistance, in part by compromising DNA 
repair capacity. 
 
Cytotoxic autophagy 
While these as well as other studies 
have found radiation-induced autophagy to 
be cytoprotective (Ito et al., 2005; Lomona-
co et al., 2009), our laboratory has demon-
strated that autophagy can likewise have a 
cytotoxic function in the radiosensitization 
of breast tumor cells (Wilson et al., 2011; 
Bristol et al., 2012). Specifically, the hor-
monally active form of vitamin D in com-
bination with radiation was found to eradi-
cate p53 wild-type, estrogen receptor-
positive ZR-75-1 breast tumor cells (Wilson 
et al., 2011) and MCF-7 breast tumor cells 
(Bristol et al., 2012) through the promotion 
of autophagy. In contrast to sensitization 
that occurs with pharmacological or genetic 
inhibition of the cytoprotective autophagy 
induced by radiation alone, inhibition of the 
autophagy induced by vitamin D + radia-
tion protected the breast tumor cells from 
the treatment combination (Wilson et al., 
2011; Bristol et al., 2012).  
Studies by Moretti et al. (2009) also 
demonstrated that promotion of autophagy 
can enhance sensitivity to radiation in 
breast tumor cells. In this report, the Pan-
caspase inhibitor, Z-VAD, was shown to 
sensitize MDA-MB231 cells to radiation 
both in cell culture and in a tumor xenograft 
model. Taken together, these studies 
demonstrate the dual and opposing func-
tions of autophagy in relation to breast tu-
mor cell sensitivity to radiation.  
 
Conclusions  
Both cytoprotective and cytotoxic func-
tions of autophagy have been identified in 
response to radiation in breast cancer, al-
though the cytotoxic functions required the 
involvement of vitamin D/vitamin D ana-
logs or a blockade to apoptosis. However, 
the specific signaling pathways mediating 
these dual functions of radiation induced 
autophagy have not been resolved. Fur-
thermore, the basis for autophagy-mediated 
radioresistance in breast tumor cells is not 
entirely clear, although potential effects on 
DNA repair capacity are intriguing and may 
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lead to the development of novel therapeu-
tic approaches for enhancing the efficacy of 
radiation therapy.  
 
Glioblastoma multiforme  
Current standard treatment 
The most common primary brain tumor 
arises from glial cells (termed “gliomas”), 
with glioblastoma multiforme (GBM) being 
the most prevalent and aggressive malig-
nant primary brain tumor (Furnari et al., 
2007). The median age of GBM diagnosis 
is approximately 64 years old, with the dis-
ease appearing more commonly in men 
than women and in Caucasians than Afri-
can-Americans (Ostrom et al., 2013). Ap-
proximately 50,000 new cases were diag-
nosed between 2006-2010 in the United 
States alone (Ostrom et al., 2013).  
GBMs are technically a subtype of as-
trocytoma, the most common form of glio-
ma (accounting for roughly 75 % of diag-
nosed cases) (Ostrom et al., 2013). The 
World Health Organization (WHO) classes 
astrocytomas into four prognostic grades (I-
IV). As the grade increases, so does the ag-
gressiveness of the neoplasm. GBMs, 
classed as grade IV, are significantly more 
proliferative and invasive than their grade I-
III counterparts (Kleihues and Cavanee, 
2000). As such, the current median survival 
time of GBM patients is a mere 12-15 
months, even with aggressive therapy 
(Stupp et al., 2005). 
The first step in GBM treatment in-
volves neurosurgical resection followed by 
adjuvant chemo- and radiotherapy (Omuro 
and DeAngelis, 2013). Radiotherapy is typ-
ically given as a 60 Gy dose divided into 30 
fractions, and the DNA alkylating agent 
temozolomide is orally administered along-
side the radiation treatment (Stupp et al., 
2005). Additionally, the FDA has approved 
another alkylating agent, carmustine, which 
can be implanted as an impregnated wafer 
following surgical resection of the tumor 
(Omuro and DeAngelis, 2013). Recently, 
bevacizumab (a VEGF monoclonal anti-
body that works to prevent angiogenesis) 
has come under investigation as a first-line 
agent to be used in combination with radia-
tion and temozolomide, but the efficacy of 
this treatment remains to be demonstrated 
(Gilbert et al., 2013; Wick et al., 2013). As 
it stands, there is a clear need for new ther-
apies and strategies exploiting untapped and 
largely uncharacterized mechanisms in or-
der to better control and ultimately cure this 
devastating disease. 
 
Autophagy in glioblastoma multiforme 
Few studies have been conducted inves-
tigating the “natural” function of autophagy 
in GBM. Several early reports provided ev-
idence that spontaneous autophagy was re-
duced in GBM (Ito et al., 2005; Kanzawa et 
al., 2004; Paglin et al., 2001). The first ex-
tensive study involving the expression of a 
key autophagy-regulating protein, Beclin-1, 
in the context of gliomas was published in 
2007 (Miracco et al., 2007). Examining 
over 200 primary brain tumor samples, 
Miracco and coworkers found decreasing 
expression of Beclin-1 with increasing tu-
mor grade. Importantly, Beclin-1 mRNA 
expression was significantly lower in GBM 
samples when compared to normal brain 
tissue extracted from the same patient. 
In a follow-up report, they examined 
cytoplasmic Beclin 1 expression as a prog-
nostic indicator for high-grade gliomas. 
They found that a high cytoplasmic Beclin-
1 score positively correlated with patient 
survival and improved performance status 
(Pirtoli et al., 2009). Conversely, a decrease 
in cytoplasmic Beclin-1 indicated tumors 
with a higher cell proliferation rate and a 
decreased incidence of apoptosis. A similar 
line of investigation found that another 
marker of autophagy, LC3, was also a 
prognostic indicator for GBM. High ex-
pression of LC3 was likewise predictive of 
improved survival of GBM patients (with a 
poor functional performance score) (Aoki et 
al., 2008). These studies reinforce the ob-
servation that autophagy is downregulated 
in the most advanced forms of gliomas. 
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Research such as this, and related work 
done in other cancer types, have given sup-
port to the idea that targeting autophagy 
might open up novel strategies for tumor 
treatment, especially for diseases like the 
highly aggressive and lethal GBM (see 
(Lefranc and Kiss, 2006), for perspective). 
Several studies have investigated the role 
current therapies have on the autophagic 
process in GBM, as well as novel treat-
ments specifically targeting autophagy as 
their primary mechanism of action. Many 
laboratories have spent much time search-
ing for unique pathways and targets to ra-
diosensitize high-grade gliomas and thus 
extend the life expectancy of patients af-
flicted with GBM. Efforts over the past 
decade have clearly made a case for the 
modulation of autophagy as one way in 
which to enhance current chemo-radiation 
treatment. 
 
Manipulating autophagy as therapeutic 
strategy 
While the literature examining au-
tophagic markers as prognostic indicators 
for GBM all seem to agree that a decrease 
in autophagy implies a more aggressive 
disease, the work done on targeting auto-
phagy for radiosensitization paints a much 
murkier picture. GBM cells are known to 
be particularly radioresistant and the result-
ing effects of autophagy on these cells after 
irradiation (IR) is conflicting. Some studies 
have shown that activation of autophagy 
after IR leads to cell death, while others 
have demonstrated that autophagy actually 
has a cytoprotective role and its activation 
leads to enhanced cell survival (Zhuang et 
al., 2009). Specifically, some of the earliest 
work found that after IR, glioma cells un-
derwent cell cycle arrest and autophagy 
without subsequent apoptosis (Ito et al., 
2005). Treatment with the potent autophagy 
inhibitors 3-methyladenine (3MA) and ba-
filomycin A1 resulted in enhanced radio-
sensitivity. This radiosensitivity was pre-
sumably mediated by impaired DNA repair, 
as more pronounced and prolonged -
H2AX foci, a marker for DNA double 
strand breaks, was also noted. These results 
suggest that, at least in a subset of malig-
nant glioma cells, the inhibition of autopha-
gy could be a viable option for radiosensiti-
zation. 
A more comprehensive study released 
in 2012 provides conflicting results (Pa-
lumbo et al., 2012). Two different glioma 
cell lines with known differences in radio-
sensitivity were used. The more radiosensi-
tive cells, as expected, were susceptible to 
low- and intermediate-doses of radiation 
and associated with autophagy activation. 
siRNA-mediated knockdown of Beclin-1 
and ATG-7 abrogated radiosensitivity, ei-
ther alone or in combination with te-
mozolomide (Palumbo et al., 2012). How-
ever, this result was not observed with the 
more radioresistant glioma cells, in contrast 
to the earlier report which showed no such 
radiation dose bias upon pharmacological 
inhibition of autophagy (Ito et al., 2005). 
Interestingly, rapamycin-induced autophagy 
activation not only increased the radiosensi-
tivity of the more radiosensitive glioma 
cells, as expected, the more radioresistant 
cells were equally radiosensitized (Palumbo 
et al., 2012). While this observation could 
be caused by some sort of off-target effect 
affecting these two cell lines differently, it 
supports the notion that autophagy modula-
tion could increase the radiosensitivity of 
glioma cells. A more likely explanation is 
that the two glioma cell lines differing in 
radiosensitivity chosen for this study have 
other genetic differences that might con-
tribute. 
In line with these results, work per-
formed combining high-linear energy trans-
fer (high-LET) radiation with oxaliplatin-
induced autophagy and significantly de-
creased xenografted GBM tumor growth 
when compared to radiation alone (Benzina 
et al., 2008). In vitro, human GBM cells 
experienced significantly more DNA DSBs 
when the combination treatment was deliv-
ered. Interestingly, it was shown that expo-
sure to both oxaliplatin and high-LET ra-
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diation induced autophagy in a dose-
dependent manner. When the glioma cells 
were transplanted into the flanks of nude 
mice, the combined treatment with oxali-
platin and radiation significantly decreased 
tumor growth with no overt signs of toxici-
ty (Benzina et al., 2008). These findings 
support the idea that autophagy and en-
hanced radiosensitivity go hand-in-hand. 
It is well known that autophagy is chief-
ly regulated by the mammalian target of 
rapamycin (mTOR) pathway (Meijer and 
Codogno, 2004), a pathway which is also 
known to play a role in radioresistance 
(Kim et al., 2006). Therefore, it was hy-
pothesized that inhibition of AKT/mTOR 
signaling could have an anticancer/radio-
sensitizing effect. To this end, two versions 
of the same glioma cells were treated with 
an AKT inhibitor (Fujiwara et al., 2007). 
Using human malignant glioma cells, as 
well as a matched radioresistant glioma var-
iant expressing the constitutively active ep-
idermal growth factor receptor variant III 
(EGFRvIII) resulting in increased AKT 
signaling, it was demonstrated that AKT 
inhibition reduced cell viability and activat-
ed autophagy, but not apoptosis, in both cell 
lines. Thus, it was concluded that AKT in-
hibition radiosensitized both glioma cell 
lines by enhancing autophagy. 
This observation was recently partially 
corroborated in a study using the dual phos-
phatidylinositol 3-kinase (PI3K)/mTOR in-
hibitor NVP-BEZ235, a drug which is cur-
rently being evaluated in a phase 1 clinical 
trial (Cerniglia et al., 2012). Exposure of 
glioma cells to NVP-BEZ235 significantly 
increased radiosensitivity. However, knock-
down of AKT1, p110α, or mTOR, while 
still demonstrating increased radiosensitivi-
ty, was not able to show the same degree of 
response seen with the drug-treated cells. 
Additional experiments suggested that 
NVP-BEZ235 also interfered with DNA 
repair, providing a possible mechanism for 
the underlying difference. Interestingly, 
while NVP-BEZ235 treatment induced au-
tophagy and radiosensitized cells, these ef-
fects occur by distinct mechanisms. When 
autophagy inhibitors were added to the 
NVP-BEZ235 and radiation combination, 
significantly more radiosensitization/cell 
killing was recorded, suggesting that, at 
least with this pharmacological agent, the 
induction of autophagy was actually cyto-
protective (Cerniglia et al., 2012). It should 
be noted, however, that these experiments 
were conducted only in head and neck 
squamous cell carcinoma cells (the other 
line used in the study), so the effect of 
NVP-BEZ235 on glioma cells could be dif-
ferent and thus remains unclear. Further-
more, off-target effects on NVP-BEZ235 
cannot be ruled out, and equally possible, 
less than 100 % knockdown of these key 
players could also affect the interpretation 
of these findings. 
An expanding body of literature indi-
cates that glioma stem cells (GSCs) identi-
fied as the CD133+ subpopulation of cells 
within the GBM tumor mass is actually re-
sponsible for the initiation and growth of 
the malignancy. As these GSCs have been 
implicated as the underlying cause of radio-
resistance (Bao et al., 2006; Beier et al., 
2007), it would be of great interest to target 
this type of cells to enhance the efficacy of 
radiotherapy. One study reported that 
CD133+ GSCs induced autophagy after ra-
diation and these cells could be radiosensi-
tized by inhibiting autophagy (Lomonaco et 
al., 2009). It was noted that CD133+ GSCs 
expressed higher levels of the autophagy-
associated proteins ATG-5, ATG-12, and 
LC3. The use of bafilomycin A1 or 
shRNA-mediated knockdown of ATG-5 
and Beclin-1 resulted in significant radio-
sensitization of the CD133+ population. 
Therefore, it was concluded that the inhibi-
tion of autophagy could be an effective 
strategy to induce radiosensitivity in GSCs. 
However, this finding is also contested. 
A subsequent study found that transient ex-
posure of GSCs to rapamycin induced cel-
lular differentiation and significantly in-
creased radiosensitivity by activating au-
tophagy (Zhuang et al., 2011). In vitro, the 
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combination of radiation and rapamycin 
treatment prevented the formation of intra-
cranial GBMs after GSCs were inoculated 
into nude mice. Additional in vivo experi-
ments demonstrated that the rapamycin and 
radiation regimen reduced tumor growth 
and increased the survival of mice. Finally, 
isolated GSCs exposed to rapamycin and 
radiation showed reduced viability and 
clonogenicity. These effects were all abol-
ished when GSCs were triple-treated with 
rapamycin, radiation, and 3MA, indicating 
that the rapamycin effect was indeed due to 
autophagy induction (Zhuang et al., 2011). 
This work suggests that autophagy plays a 
key role in the regulation of the differentia-
tion and radiosensitivity of GSCs, though in 
contrast to previous work, it infers that the 
induction of autophagy, not the inhibition, 
mediates these outcomes. 
 
Conclusions 
GBM is a highly aggressive and fatal 
disease. While astounding strides have been 
made for other cancer types in terms of im-
proved survival and quality of life, glioma 
patients still lag significantly behind. Novel 
therapeutic strategies desperately need to be 
brought to the clinic to combat this devas-
tating malignancy. 
The role of autophagy in neoplastic 
progression, and the response to various 
anticancer agents and treatments, remains 
multifaceted and unclear. On the one hand, 
autophagy provides a pathway by which 
cancer cells can “clean out” and recycle 
damaged and possibly deleterious orga-
nelles and proteins. On the other hand, the 
induction of autophagy opens up an avenue 
by which cell death can occur in the face of 
defective apoptosis. In some patients, in 
certain contexts, the induction or inhibition 
of autophagy could therefore be used to en-
hance existing treatments, especially radio-
therapy. The work reviewed in this section 
illustrates this point – for seemingly every 
study which suggests that inhibition of au-
tophagy radiosensitizes glioma cells, anoth-
er group releases a similar report with a 
conflicting result. It is clear that these types 
of experiments need to be carried out under 
explicitly defined conditions using isogenic 
cells differing in only one gene and funda-
mental characteristic. 
The contextual importance of GBM an-
ti-neoplastic therapy is not limited to au-
tophagy. For example, recent work has 
demonstrated that the in vivo inhibition of 
ataxia-telangiectasia mutated (ATM), a ki-
nase critically involved in the DNA damage 
response (Valerie and Povirk, 2003), was 
most successful in radiosensitizing human 
glioma cells with a mutant p53 background 
(Biddlestone-Thorpe et al., 2013). It is well 
established that classic autophagy is p53-
mediated (Green and Kroemer, 2009; Ken-
zelmann Broz et al., 2013; Tasdemir et al., 
2008). Therefore, if gliomas with mutant 
p53 undergo radiosensitization and apopto-
sis more readily than wild type cells it is 
likely that, under these circumstances, p53 
acts to preserve cellular integrity and sur-
vival through an autophagic process. As 
p53 wild type cells are, by some accounts, 
more prone to undergo autophagy, it can be 
interpreted that the induction of autophagy 
in gliomas is functioning in a cytoprotective 
manner. Regardless, the differential p53 
response to ATM inhibition opens up an 
excellent therapeutic opportunity for target-
ing gliomas in a cancer-specific manner 
while protecting normal brain. 
A growing body of literature has made 
it clear that there is no “one size fits all” 
strategy by which we can hope to effective-
ly treat all cases of GBM. Rather, it will be 
important to develop patient-specific treat-
ment plans which involve manipulating au-
tophagy or other cellular processes to max-
imize therapeutic efficacy and patient sur-
vival. Though much work remains to be 
done, it is evident that autophagy modula-
tion offers a promising, novel approach to 
GBM treatment.  
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